Colleen L. Barry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Colleen L. Barry has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Brendan Saloner
Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University , 615 N Wolfe St, Baltimore, MD 21205, United States
2 shared publications - Sachini Bandara
Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2 shared publications - Alene Kennedy-Hendricks
Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland
1 shared publication - Bradley D. Stein
RAND Pittsburgh Pennsylvania USA
1 shared publication - Erika Franklin Fowler
Wesleyan University
1 shared publication - Jeff Niederdeppe
Cornell University
1 shared publication
Latest Publications
- Open Access
- 27 January 2026
- Published by Oxford University Press (OUP) in Human Communication Research
- Vol. 52 (4) , 221-233
Testing message strategies that minimize White Americans’ backlash to racial equity information
Scholars have worried that messages about racial equity can produce backlash from White respondents. Drawing upon psychological reactance theory, we compared cognitive and affective responses to a message emphasizing how a redistributive policy would benefit everyone (universalist message) to a message that also emphasized how the policy would especially benefit minoritized racial groups (targeted universalist message) among a sample of 871 White Americans. Participants in the targeted universalist condition experienced more anger, endorsed more harmful stereotypes about racial outgroups, and saw the government as less responsible for addressing poverty than participants in the universalist condition. Mediation analyses suggest that anger, stereotyping, and perceived government responsibility have a negative, indirect effect on policy support. Our findings underscore the need for future work to identify strategies for communicating about racial equity that avoid activating harmful stereotypes.
- 27 January 2026
- Published by Oxford University Press (OUP) in Human Communication Research
- Vol. 52 (4) , 221-233
Open AccessTesting message strategies that minimize White Americans’ backlash to racial equity information
Scholars have worried that messages about racial equity can produce backlash from White respondents. Drawing upon psychological reactance theory, we compared cognitive and affective responses to a message emphasizing how a redistributive policy would benefit everyone (universalist message) to a message that also emphasized how the policy would especially benefit minoritized racial groups (targeted universalist message) among a sample of 871 White Americans. Participants in the targeted universalist condition experienced more anger, endorsed more harmful stereotypes about racial outgroups, and saw the government as less responsible for addressing poverty than participants in the universalist condition. Mediation analyses suggest that anger, stereotyping, and perceived government responsibility have a negative, indirect effect on policy support. Our findings underscore the need for future work to identify strategies for communicating about racial equity that avoid activating harmful stereotypes.
- 23 August 2022
- Published by Springer Nature in Community Mental Health Journal
- Vol. 59 (2) , 205-208
Creating Comprehensive Crisis Response Systems: An Opportunity to Build on The Promise of 988
The implementation of a national suicide prevention hotline is imminent and will need to be supported by comprehensive crisis systems, which are currently rarely implemented in part due to their cost. In this Commentary paper we identify three core components of a high-functioning, integrated crisis service system. We identified regional crisis call centers, mobile response teams, and crisis receiving and stabilization centers as core components of an integrated crisis service system. We then outline how this approach has been used in Arizona. Building out these systems and sustainable funding models to support these systems is necessary to ensure that 988 implementation lives up to the promise of creating a lifeline to support services for individuals in crisis.
- 23 August 2022
- Published by Springer Nature in Community Mental Health Journal
- Vol. 59 (2) , 205-208
Creating Comprehensive Crisis Response Systems: An Opportunity to Build on The Promise of 988
The implementation of a national suicide prevention hotline is imminent and will need to be supported by comprehensive crisis systems, which are currently rarely implemented in part due to their cost. In this Commentary paper we identify three core components of a high-functioning, integrated crisis service system. We identified regional crisis call centers, mobile response teams, and crisis receiving and stabilization centers as core components of an integrated crisis service system. We then outline how this approach has been used in Arizona. Building out these systems and sustainable funding models to support these systems is necessary to ensure that 988 implementation lives up to the promise of creating a lifeline to support services for individuals in crisis.
- 1 January 2022
- Published by SAGE Publications in Substance Abuse
- Vol. 43 (1) , 682-690
A Bridge Too Far? Distance to Waivered Physicians and Utilization of Buprenorphine Treatment for Opioid use Disorder in West Virginia Medicaid
Background: Travel distance to medication treatment for opioid use disorder (OUD) is a challenge for many patients, but little is known about how distance is associated with medication treatment utilization. This study examines the association between distance to the nearest physician waivered to prescribe buprenorphine and patient-level buprenorphine treatment among West Virginia Medicaid expansion enrollees with diagnosed OUD. Methods: We conducted a cross-sectional spatial analysis with 2016 Medicaid claims data, separately examining individuals living in metropolitan and non-metropolitan areas. We calculated the driving distance from the centroid of patients’ residential ZIP codes to the street address of the nearest waivered physician derived from the 2015 Drug Enforcement Administration listing. Regression models examined the association between distance and initiation and duration of buprenorphine (among those initiating). Results: We focused on 8,008 individuals with OUD in 2016. The nearest waivered prescriber in metropolitan areas was an average of 7.13 miles away from patients’ residential ZIP codes and 14.54 miles in non-metropolitan areas. The providers they actually visited were a mean of 33.63 miles away in metro areas and 46.36 in non-metropolitan areas. In multivariable analyses, compared to those living 20 miles from a waivered physician was associated with −32.13 fewer days of treatment (95% CI: −57.86, −6.40) in metro areas and −16.70 fewer days in non-metro areas (95% CI: −32.32, −1.08). Conclusions: Longer travel distance to buprenorphine treatment is associated with a shorter duration of care that is likely to be clinically meaningful.
- 1 January 2022
- Published by SAGE Publications in Substance Abuse
- Vol. 43 (1) , 682-690
A Bridge Too Far? Distance to Waivered Physicians and Utilization of Buprenorphine Treatment for Opioid use Disorder in West Virginia Medicaid
Background: Travel distance to medication treatment for opioid use disorder (OUD) is a challenge for many patients, but little is known about how distance is associated with medication treatment utilization. This study examines the association between distance to the nearest physician waivered to prescribe buprenorphine and patient-level buprenorphine treatment among West Virginia Medicaid expansion enrollees with diagnosed OUD. Methods: We conducted a cross-sectional spatial analysis with 2016 Medicaid claims data, separately examining individuals living in metropolitan and non-metropolitan areas. We calculated the driving distance from the centroid of patients’ residential ZIP codes to the street address of the nearest waivered physician derived from the 2015 Drug Enforcement Administration listing. Regression models examined the association between distance and initiation and duration of buprenorphine (among those initiating). Results: We focused on 8,008 individuals with OUD in 2016. The nearest waivered prescriber in metropolitan areas was an average of 7.13 miles away from patients’ residential ZIP codes and 14.54 miles in non-metropolitan areas. The providers they actually visited were a mean of 33.63 miles away in metro areas and 46.36 in non-metropolitan areas. In multivariable analyses, compared to those living 20 miles from a waivered physician was associated with −32.13 fewer days of treatment (95% CI: −57.86, −6.40) in metro areas and −16.70 fewer days in non-metro areas (95% CI: −32.32, −1.08). Conclusions: Longer travel distance to buprenorphine treatment is associated with a shorter duration of care that is likely to be clinically meaningful.
Methadone and buprenorphine treatment in United States jails and prisons: lessons from early adopters
Aims: To identify implementation barriers and facilitators to the adoption and implementation of programs that provide opioid agonist treatments (OAT) with methadone and buprenorphine to treat opioid use disorder in jails and prisons in the United States.Design: Qualitative analysis: semi‐structured interviews were conducted and thematic analyses of transcripts and notes were performed using a hybrid inductive/deductive coding approach.Setting: Jails and prisons in the United States.Participants: From August 2019 to January 2020, we conducted 20 key informant interviews with 35 individuals representing 19 carceral systems that both initiate and maintain OAT.Measurements: Interviews covered four domains: (1) program adoption; (2) policy influence on implementation; (3) program structure; and (4) program outcomes.Findings: Stigma among staff, particularly medical staff, challenged program adoption, but reduced over time as staff were exposed to the program. Regulations on OAT dispensation, such as licensing requirements and prescribing limits, were key challenges to program implementation and shaped program structure. Dispensing medication required significant staff, time and space. Facilities were further challenged to overcome stigma and concerns about diversion, as OAT medication is often treated as contraband in carceral settings. Some systems deviated from evidence‐based treatment by limiting OAT dosage to low levels, requiring counseling for participation and requiring detoxification before medication initiation. Despite these challenges, early adopters felt strongly that other jails and prisons in the United States should provide OAT and that legislation and litigation may soon force OAT expansion in these carceral settings.Conclusions: Despite identifying regulatory and logistical challenges, early adopters of opioid agonist treatment (OAT) programs in US jails and prisons demonstrate that OAT programs can successfully be implemented in carceral settings with tailoring to the specific context.
Methadone and buprenorphine treatment in United States jails and prisons: lessons from early adopters
Aims: To identify implementation barriers and facilitators to the adoption and implementation of programs that provide opioid agonist treatments (OAT) with methadone and buprenorphine to treat opioid use disorder in jails and prisons in the United States.Design: Qualitative analysis: semi‐structured interviews were conducted and thematic analyses of transcripts and notes were performed using a hybrid inductive/deductive coding approach.Setting: Jails and prisons in the United States.Participants: From August 2019 to January 2020, we conducted 20 key informant interviews with 35 individuals representing 19 carceral systems that both initiate and maintain OAT.Measurements: Interviews covered four domains: (1) program adoption; (2) policy influence on implementation; (3) program structure; and (4) program outcomes.Findings: Stigma among staff, particularly medical staff, challenged program adoption, but reduced over time as staff were exposed to the program. Regulations on OAT dispensation, such as licensing requirements and prescribing limits, were key challenges to program implementation and shaped program structure. Dispensing medication required significant staff, time and space. Facilities were further challenged to overcome stigma and concerns about diversion, as OAT medication is often treated as contraband in carceral settings. Some systems deviated from evidence‐based treatment by limiting OAT dosage to low levels, requiring counseling for participation and requiring detoxification before medication initiation. Despite these challenges, early adopters felt strongly that other jails and prisons in the United States should provide OAT and that legislation and litigation may soon force OAT expansion in these carceral settings.Conclusions: Despite identifying regulatory and logistical challenges, early adopters of opioid agonist treatment (OAT) programs in US jails and prisons demonstrate that OAT programs can successfully be implemented in carceral settings with tailoring to the specific context.